Pace Life Sciences, the life sciences division of science and technology company Pace, has named Andrew (Andy) Fenny as its President.
“Pace Life Sciences has a strong foundation of scientific expertise, technical talent, and customer commitment,” said Fenny. “As life sciences organizations look for partners who can help deliver with speed and accuracy amidst evolving challenges, Pace is well positioned to deliver integrated support so these organizations can move forward with greater confidence and continuity.”
“Andy joins Pace at a time when our customers need more than results. They need a partner who can help them navigate complex regulatory pathways and challenging market conditions,” said Ken Beyer, CEO at Pace. “Andy’s leadership and expertise will help us deliver the certainty companies need at every stage of the product lifecycle because every phase drives programs closer to patients waiting on treatments that change lives.”
About Andy Fenny
As President, Fenny will oversee all aspects of the division, strengthen collaboration across all eight Pace Life Sciences sites, and direct how the organization delivers its services to customers from early development through clinical supply and commercialization. He will focus on expanding support and capacity for pharmaceutical and biotech clients across the development cycle.
Fenny brings more than 20 years of leadership experience across the CDMO and pharmaceutical sectors. He joins Pace Life Sciences from SK pharmteco, where he served as Chief Commercial Officer. Before that, he was Chief Business Officer at FUJIFILM Diosynth Biotechnologies (now FUJIFILM Biotechnologies). His expertise spans commercial strategy, business development, integrated operations and client experience.
About Pace Life Sciences
Pace Life Sciences operates eight sites across the United States, serving pharmaceutical and biotech companies ranging from emerging innovators advancing new drug candidates to established companies managing commercial products. Its Analytical Center of Excellence in Research Triangle Park offers stability testing and storage, extractables and leachables testing, analytical method development and validation, and spectroscopy for characterizing small and large molecules. These services are supported by recent investments in advanced instrumentation such as high-field NMR, high-resolution mass spectrometry and X-ray diffraction. The site has also added water microbiology testing to support North Carolina’s growing pharmaceutical manufacturing industry. Pace is a portfolio company of Leonard Green & Partners and Aurora Capital Partners.
